Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Catalytic asymmetric construction of remote P or other heteroatom (Si/S) stereogenic axially chiral scaffolds

Wenqi Liu, Zhijie Ling, Yang-Zi Liu* and Wei-Ping Deng*
Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, College of Chemistry and Materials Science, Zhejiang Normal University, 688 Yingbin Road, Jinhua, Zhejiang 321004, China. E-mail: liuyangzi@zjun.edu.cn; dengwp827@zjnu.edu.cn

Received 21st October 2025 , Accepted 3rd November 2025

First published on 4th November 2025


Abstract

Axial chirality represents a fundamental element of stereochemistry and is a defining structural feature in many chiral compounds. Although the axial chirality of atropisomers, allenes and spiranes has been extensively studied, the chemistry of alkylidenecycloalkanes and their analogues—especially those possessing P-, S- or Si-based axial chirality—remains underdeveloped. Here we report a chiral phosphoric acid-catalyzed oxime condensation that enables the construction of remote heteroatom (P/S/Si)-stereogenic axially chiral scaffolds. The reaction accommodates a broad range of functional groups, delivering optically active axially chiral 9-heteroanthrone-based oxime ethers in good to excellent enantioselectivities (up to 98[thin space (1/6-em)]:[thin space (1/6-em)]2 er). We also describe a modular synthesis of dibenzoazaphosphepinones and demonstrate their application as chiral monodentate phosphine ligands in asymmetric catalysis.


Introduction

Axially chiral compounds have garnered significant attention in synthetic1,2 and pharmaceutical3 chemistry due to their presence in natural products and diverse applications4–6 as bioactive drug molecules,7–9 chiral ligands and catalysts,10,11 and functional materials like liquid crystals.12 Advances in catalytic asymmetric synthesis over recent decades have established robust methods for constructing axially chiral compounds, particularly (hetero)aryl-based X–Y (X, Y = C, N) systems13–31 and allenes,32–34 making this a vibrant subfield within asymmetric catalysis. These advances have stimulated exploration of novel axially chiral skeletons.22,30,35–37 In contrast to classical atropisomers, allenes and spiranes constitute a distinct class of non-atropisomeric axially chiral compounds that has recently garnered increasing attention.34 The hybridization of alkene and spirane structural motifs gives rise to a distinctive class of non-atropisomeric axial stereoisomerism, termed alkylidene-cyclic molecules. However, investigation into this axial stereoisomerism is still limited36,37 (Scheme 1A). Early synthetic approaches to such architectures typically relied on non-catalytic methods.38–44 A landmark study by Fiaud et al. in 1988 described the enantioselective synthesis of 4-alkylcyclohexylbenzene derivatives via asymmetric palladium catalysis,45 yet this strategy remained largely overlooked for years. Recently, more efficient routes to these novel skeletons have emerged, including: (i) photochemical deracemization of racemic alkylidenecycloalkanes;46,47 (ii) enantioselective [2 + 2] cycloadditions between terminal alkenes and allenoates or allenyl imides;48,49 (iii) transition metal-catalyzed desymmetrization of functionalized cycloalkanes;50–61 and (iv) enantioselective functionalization of cyclic carbonyl compounds62–71 (Scheme 1B).
image file: d5sc08143b-s1.tif
Scheme 1 Enantioselective synthesis of axially chiral alkylidenecycloalkanes.

Notably, the construction of axially chiral tricyclic aromatic scaffolds bearing remote heteroatom (P/S/Si)-stereogenic centers remains rare. This may be attributed to the challenge of exercising stereocontrol at distal heteroatom sites: while desymmetrization of monocyclic substrates enables effective control of carbon stereocenters, the bulky tricyclic aromatic framework complicates stereochemical manipulation at remote P/S/Si centres.66 Moreover, substitution of distal carbon atoms with phosphorus, sulfur or silicon elongates the C(sp2)–P(sp3), C(sp2)–S(sp3), C(sp2)–Si(sp3) bonds relative to C(sp2)–C(sp3), increasing ring strain and conformational constraint. The inherent structural distortion in 9-heteroanthrones may further complicate precise stereochemical control72 (Scheme 1C).

Inspired by these precedents and the potential applications of 9-heteroanthrones,73–76 we envisioned a chiral phosphoric acid-catalyzed enantioselective condensation between 9-heteroanthrones and hydroxylamines to construct axially chiral 9-heteroanthrone-based oxime ethers (Scheme 1D). We proposed that stereocontrol in this condensation would arise during the dehydration step, wherein the CPA catalyst engages the NH group via hydrogen bonding and activates the hydroxyl group through protonation to facilitate water elimination65 (Scheme 1C). Moreover, in this work, we also developed a modular synthesis of dibenzoazaphosphepinones via axial-to-point chirality conversion from 9-phosphaanthrone-derived oxime ethers and explored their applications as chiral monodentate phosphine ligands in asymmetric reactions (Scheme 1D).

Results and discussion

We began our investigation by examining the model reaction between 5-phenyl-10H-acridophosphin-10-one 5-oxide (1a) and O-(4-nitrophenyl)hydroxylamine (2a) using a series of chiral phosphoric acid (CPA) catalysts with varied scaffold structures in DCE at 60 °C (Table 1, entries 1–7). The less sterically encumbered CPA C1 afforded only trace product (entry 1). Pleasingly, C2 delivered the target product 3a in 65% yield with 93.5[thin space (1/6-em)]:[thin space (1/6-em)]6.5 enantiomeric ratio (er) (entry 2). Both the 2,4,6-tricyclohexyl-substituted C3 and the 9-phenanthrenyl-based C4 afforded moderate enantioselectivity (85[thin space (1/6-em)]:[thin space (1/6-em)]15–87.5[thin space (1/6-em)]:[thin space (1/6-em)]12.5 er) but with diminished yields (entries 3–4). The 8H-binaphthyl-derived CPA C5 provided acceptable yield and er (entry 5). The 2,4,6-triisopropyl-substituted spirocyclic CPA C6 yielded only trace product (entry 6), whereas the 9-phenanthrenyl-substituted spirocyclic CPA C7 afforded good enantioselectivity (93[thin space (1/6-em)]:[thin space (1/6-em)]7 er) with 79% yield (entry 7). Subsequent solvent screening identified CCl4 as the optimal choice, delivering improved enantioselectivity (97[thin space (1/6-em)]:[thin space (1/6-em)]3 er, entries 8–15). Reducing the temperature to 50 °C maintained high stereocontrol but lowered the yield (75%, entry 16). Omitting molecular sieves or reducing the catalyst loading adversely affected reaction efficiency (55–67%, entries 17 and 18). Further optimization (see SI) established the standard conditions: C2 (10 mol%) and 5 Å molecular sieves (50 mg) in CCl4 (0.3 mL) at 60 °C for 72 hours.
Table 1 Optimization of the reaction conditionsa

image file: d5sc08143b-u1.tif

a Reaction conditions: 1a (0.10 mmol), 2a (0.12 mmol), CPA (10 mol%) and 5 Å molecular sieves (50 mg) in solvent (0.3 mL) at 60 °C for 72 h unless otherwise noted.b Isolated yield.c Enantiomeric ratio (er) determined by chiral HPLC analysis.d Reaction performed at 50 °C.e Without 5 Å molecular sieves.f With 5 mol% catalyst loading.
Entry CPA Solvent Yieldb (%) erc (%)
1 C1 DCE Trace
2 C2 DCE 65 93.5[thin space (1/6-em)]:[thin space (1/6-em)]6.5
3 C3 DCE 49 87.5[thin space (1/6-em)]:[thin space (1/6-em)]12.5
4 C4 DCE 12 85[thin space (1/6-em)]:[thin space (1/6-em)]15
5 C5 DCE 57 92.5[thin space (1/6-em)]:[thin space (1/6-em)]7.5
6 C6 DCE Trace
7 C7 DCE 79 93[thin space (1/6-em)]:[thin space (1/6-em)]7
8 C2 PhCl 63 89[thin space (1/6-em)]:[thin space (1/6-em)]11
9 C2 PhCF3 83 87.5[thin space (1/6-em)]:[thin space (1/6-em)]12.5
10 C2 Toluene 65 91[thin space (1/6-em)]:[thin space (1/6-em)]9
11 C2 DCM 57 93.5[thin space (1/6-em)]:[thin space (1/6-em)]6.5
12 C2 CHCl3 47 82[thin space (1/6-em)]:[thin space (1/6-em)]18
13 C2 CCl4 99 97[thin space (1/6-em)]:[thin space (1/6-em)]3
14 C2 THF Trace
15 C2 Decaline 35 95[thin space (1/6-em)]:[thin space (1/6-em)]5
16d C2 CCl4 75 96.5[thin space (1/6-em)]:[thin space (1/6-em)]3.5
17e C2 CCl4 55 96[thin space (1/6-em)]:[thin space (1/6-em)]4
18f C2 CCl4 67 96.5[thin space (1/6-em)]:[thin space (1/6-em)]3.5


With optimized conditions in hand, we first explored the substrate scope with respect to the hydroxylamine component (Table 2, A). Using O-(4-tert-butylphenyl)hydroxylamine (2b) afforded oxime ether 3b in 93% yield and 97[thin space (1/6-em)]:[thin space (1/6-em)]3 er. A phenyl substituent at the para-position gave 3c in 85% yield with 95[thin space (1/6-em)]:[thin space (1/6-em)]5 er. Hydroxylamines bearing an OCF3 group provided 3d in 92% yield and 95.5[thin space (1/6-em)]:[thin space (1/6-em)]4.5 er. Other electron-withdrawing para-substituents—halogen (2e), ester (2f) and cyano (2g)—participated effectively, yielding products (3e–3g) with high stereoselectivity (90–93% yield, 94.5[thin space (1/6-em)]:[thin space (1/6-em)]5.5–96.5[thin space (1/6-em)]:[thin space (1/6-em)]3.5 er). meta-Bromo (2i) and ester (2j) substituents also afforded excellent stereocontrol (94.5[thin space (1/6-em)]:[thin space (1/6-em)]5.5 and 96.5[thin space (1/6-em)]:[thin space (1/6-em)]3.5 er, respectively), while a meta-methoxy group (2h) led to lower er (89.5[thin space (1/6-em)]:[thin space (1/6-em)]10.5) and yield (75%), likely due to its electron-donating character. ortho-Substitution (2k) compromised both enantioselectivity (87[thin space (1/6-em)]:[thin space (1/6-em)]13 er) and yield (76%), presumably due to steric hindrance. Benzyl-substituted hydroxylamine 2p (95% yield, 90.5[thin space (1/6-em)]:[thin space (1/6-em)]9.5 er) and aliphatic allylic hydroxylamine 2q (85% yield, 88.5[thin space (1/6-em)]:[thin space (1/6-em)]11.5 er) also underwent efficient condensation with the selected 9-phosphaanthrone (1a). Absolute configurations were assigned based on X-ray crystallographic analysis of 3a (CCDC 2478635).

Table 2 Substrate scope with respect to 9-heteroanthrone derivatives and hydroxylamines
a Reaction conditions: (1) (0.10 mmol), (2) (0.12 mmol), (C2) (10 mol%) and 5 Å molecular sieves (50 mg) in solvent (0.3 mL) at 60 °C. Yields are isolated. The er determined by chiral HPLC analysis.b Na2SO4 used instead of 5 Å molecular sieves.c Decaline instead of CCl4.
image file: d5sc08143b-u2.tif


Given its superior reactivity and ease of product isolation, O-(4-tert-butylphenyl)hydroxylamine (2b) was selected to evaluate the substrate scope of 9-heteroanthrones (Table 2, B). para-Substituted electron-donating methyl or methoxy groups on phenyl group afforded 3r and 3s in excellent yields (90–92%) and enantioselectivities (94[thin space (1/6-em)]:[thin space (1/6-em)]6–96[thin space (1/6-em)]:[thin space (1/6-em)]4 er). The condensation tolerated electron-withdrawing para-substituents, including halogens and trifluoromethyl groups, yielding products 3t–3v with high enantioselectivity (95[thin space (1/6-em)]:[thin space (1/6-em)]5–96[thin space (1/6-em)]:[thin space (1/6-em)]4 er). Oxime ethers 3w and 3x were obtained in good yields (84–91%) from meta-substituted methyl and chlorophenyl groups. ortho-Methyl group afforded 3y in 89% yield and 94.5[thin space (1/6-em)]:[thin space (1/6-em)]5.5 er. 3,5-Dimethyl-phenyl 9-phosphaanthrone reacted smoothly to give 3z (86% yield, 96[thin space (1/6-em)]:[thin space (1/6-em)]4 er). Reaction of cyclohexyl 9-phosphaanthracene or phosphoramidate proceeded in 80–85% yield to give 3aa or 3ab with excellent stereoselectivity (97[thin space (1/6-em)]:[thin space (1/6-em)]3–98[thin space (1/6-em)]:[thin space (1/6-em)]2 er). By contrast, 3,6- or 2,7-dimethyl-substituted 9-phosphaanthrone provided 3ac or 3ad in moderate yields (55–62%) but good enantioselectivities (91[thin space (1/6-em)]:[thin space (1/6-em)]9–94.5[thin space (1/6-em)]:[thin space (1/6-em)]5.5 er). To further demonstrate generality, we investigated the desymmetrization of 9-Si-anthrones (1ba, 1bb) and a 9-S-anthrone (1ca) for constructing remote S/Si-stereogenic axially chiral scaffolds (see SI for condition screening). Axially chiral 9-Si-anthrone-based oxime ethers (3ba, 3bb) were obtained in excellent yields with moderate to good er (83.5[thin space (1/6-em)]:[thin space (1/6-em)]16.5–86.5[thin space (1/6-em)]:[thin space (1/6-em)]13.5). The 9-S-anthrone (1ca) reacted smoothly, delivering the product (3ca) in moderate yield (69%) with moderate enantioselectivity (79[thin space (1/6-em)]:[thin space (1/6-em)]21 er) (Table 2, B). The consistently lower enantioselectivities observed for these S- and Si-containing scaffolds compared to their phosphorus analogues prompt us to consider factors beyond bond length considerations, such as the steric hindrance of substituents and other secondary effects.

We next investigated the conversion of remote phosphorus axial chirality to phosphorus-centered chirality via a Beckmann rearrangement. Pd-catalyzed deallylation of 3q (88[thin space (1/6-em)]:[thin space (1/6-em)]12 er) afforded hydroxylamine 4, which underwent a Beckmann rearrangement to give intermediate 5 (82% over two steps, 83[thin space (1/6-em)]:[thin space (1/6-em)]17 er). The slight erosion in enantioselectivity may be attributed to facile isomerization of the hydroxyl group in 4. Standing at room temperature for 24 h converted compound 5 to 7b, and subsequent trichlorosilane reduction afforded 6a in 60% yield over two steps (82.5[thin space (1/6-em)]:[thin space (1/6-em)]17.5 er). Recrystallization yielded enantiopure R-6a (>99.5[thin space (1/6-em)]:[thin space (1/6-em)]0.5 er), the structure of which was confirmed by X-ray crystallography (CCDC 2478637). Reduction of R-6a with a borane-dimethyl sulfide complex gave 7a in 65% yield with retained er (>99.5[thin space (1/6-em)]:[thin space (1/6-em)]0.5). The P(III) center in R-6a was oxidatively functionalized using H2O2, S8 and Se to furnish 7b, 7c and 7d, respectively, in excellent yields (94–99%) with complete chirality retention (>99.5[thin space (1/6-em)]:[thin space (1/6-em)]0.5 er). Treatment of 7b with Lawesson's reagent afforded thioamide 8a in 90% yield and 99[thin space (1/6-em)]:[thin space (1/6-em)]1 er. Methylation of 8a gave 9a quantitatively (99%) with 99.5[thin space (1/6-em)]:[thin space (1/6-em)]0.5 er. These transformations highlight the versatility of the method for accessing diverse functionalized products with high efficiency and stereochemical fidelity (Scheme 2).


image file: d5sc08143b-s2.tif
Scheme 2 Synthetic transformations of 3q.

Furthermore, we present R-6a—a novel cyclic triarylphosphine scaffold that was previously inaccessible in enantiopure form through conventional synthetic routes. In contrast to conventional triarylphosphines, this structure exhibits a narrower ∠C1P1C2 bond angle (98.7° vs. 102.0°) and enhanced rigidity, features that are anticipated to enhance its performance in asymmetric catalysis (Scheme 3A). Racemization studies revealed a high inversion barrier of 30.3 kcal mol−1 for R-6a in toluene at 87 °C (Scheme 3B). Notably, R-6a (>99.5[thin space (1/6-em)]:[thin space (1/6-em)]0.5 er) functioned effectively as a chiral monodentate phosphine ligand in Pd-catalyzed asymmetric allylic alkylation (Scheme 3C). For instance, the reaction of indole with (E)-1,2-diphenylallyl acetate 10 delivered the C3-phenylallyl-substituted indole 12 in 97% yield and 95.5[thin space (1/6-em)]:[thin space (1/6-em)]4.5 er. Similarly, using benzylamine 13 as the nucleophile afforded product 14 in 93% yield and 92.5[thin space (1/6-em)]:[thin space (1/6-em)]7.5 er. The absolute configurations of 12 and 14 were assigned based on literature reports.77,78 These results underscore the promising potential of cyclic chiral triarylphosphines in the field of asymmetric catalysis.


image file: d5sc08143b-s3.tif
Scheme 3 The bond angle analysis, racemization studies, and synthetic application of cyclic triarylphosphine 6a.

Conclusions

In summary, we have established an efficient and enantioselective construction of remote P/S/Si-stereogenic axially chiral frameworks from 9-heteroanthrones and hydroxylamines via chiral phosphoric acid-catalyzed asymmetric condensation. This work overcomes longstanding challenges in stereocontrol at distal heteroatom centers and provides access to a novel class of axially chiral oxime ethers in high enantiopurity (up to 98[thin space (1/6-em)]:[thin space (1/6-em)]2 er). Furthermore, these products serve as versatile platforms for diversity-oriented synthesis: through a Beckmann rearrangement, axial chirality is efficiently converted into phosphorus-centered point chirality, yielding enantioenriched dibenzoazaphosphepinones. The resulting cyclic triarylphosphine architecture not only exhibits enhanced rigidity and configurational stability but also functions as an effective chiral monodentate ligand, demonstrating promising utility in catalytic asymmetric allylation reaction. This work opens avenues for the design and application of heteroatom axially chiral systems in synthesis and catalysis.

Author contributions

W. L. performed most of the experiments, with support from Z. L. in the catalyst and substrate preparation. W. L., Y.-Z. L. and W.-P. D. conceived of the idea and designed the experiments. W. L., Y.-Z. L. and W.-P. D. wrote the manuscript. Y.-Z. L. and W.-P. D. directed the project. All authors contributed to discussions.

Conflicts of interest

There are no conficts to declare.

Data availability

CCDC 2478635 (3a) and 2478637 (6a) contain the supplementary crystallographic data for this paper.79a,b

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information: experimental procedures, characterization data, NMR spectra, HPLC traces, and additional figures supporting the results presented in the main text. See DOI: https://doi.org/10.1039/d5sc08143b.

Acknowledgements

We are grateful for the financial support from the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2022R01007), the NSFC (22201253), and the Start-up Research Grant from Zhejiang Normal University.

Notes and references

  1. J. M. Lassaletta, Atropisomerism and Axial Chirality, World Scientific, Singapore, 2019 Search PubMed.
  2. Y.-B. Wang and B. Tan, Acc. Chem. Res., 2018, 51, 534–547 CrossRef CAS.
  3. M. Basilaia, M. H. Chen, J. Secka and J. L. Gustafson, Acc. Chem. Res., 2022, 55, 2904–2919 CrossRef CAS PubMed.
  4. J. E. Smyth, N. M. Butler and P. A. Keller, Nat. Prod. Rep., 2015, 32, 1562–1583 RSC.
  5. G. Bringmann, T. Gulder, T. A. M. Gulder and M. Breuning, Chem. Rev., 2011, 111, 563–639 CrossRef CAS.
  6. S. R. LaPlante, L. D. Fader, K. R. Fandrick, D. R. Fandrick, O. Hucke, R. Kemper, S. P. F. Miller and P. J. Edwards, J. Med. Chem., 2011, 54, 7005–7022 CrossRef CAS.
  7. S. T. Toenjes and J. L. Gustafson, Future Med. Chem., 2018, 10, 409–422 CrossRef CAS PubMed.
  8. J. Clayden, W. J. Moran, P. J. Edwards and S. R. LaPlante, Angew. Chem., Int. Ed., 2009, 48, 6398–6401 CrossRef CAS PubMed.
  9. G. Bringmann, A. J. Price Mortimer, P. A. Keller, M. J. Gresser, J. Garner and M. Breuning, Angew. Chem., Int. Ed., 2005, 44, 5384–5427 CrossRef CAS PubMed.
  10. Y. Chen, S. Yekta and A. K. Yudin, Chem. Rev., 2003, 103, 3155–3212 CrossRef CAS.
  11. I. O. Betinol, Y. Kuang, B. P. Mulley and J. P. Reid, Chem. Rev., 2025, 125, 4184–4286 CrossRef CAS.
  12. G. Dotsevi, Y. Sogah and D. J. Cram, J. Am. Chem. Soc., 1976, 98, 3038–3041 CrossRef CAS.
  13. G. Liao and B.-F. Shi, Acc. Chem. Res., 2025, 58, 1562–1579 CrossRef CAS PubMed.
  14. S. Gao, L. Su and J. Liu, J. Am. Chem. Soc., 2025, 147, 23946–23956 CrossRef CAS.
  15. X. Yang, L. Su, S. Gao and J. Liu, Angew. Chem., Int. Ed., 2025, e202517629 Search PubMed.
  16. B. Ye, L. Su, K. Zheng, S. Gao and J. Liu, Angew. Chem., Int. Ed., 2025, 64, e202413949 CrossRef CAS.
  17. L. Su, S. Gao and J. Liu, Nat. Commun., 2024, 15, 7248 CrossRef.
  18. T. A. Schmidt, V. Hutskalova and C. Sparr, Nat. Rev. Chem., 2024, 8, 497–517 CrossRef PubMed.
  19. H.-H. Zhang, T.-Z. Li, S.-J. Liu and F. Shi, Angew. Chem., Int. Ed., 2024, 63, e202311053 CrossRef CAS PubMed.
  20. S.-H. Xiang, W.-Y. Ding, Y. B. Wang and B. Tan, Nat. Catal., 2024, 7, 483–498 CrossRef CAS.
  21. J. Feng, C.-J. Lu and R.-R. Liu, Acc. Chem. Res., 2023, 56, 2537–2554 CrossRef CAS.
  22. W. Qiu, R. Tao, Y. He, Y. Zhou, K. Yang and Q. Song, Nat. Commun., 2024, 15, 10432 CrossRef CAS.
  23. J. K. Cheng, S.-H. Xiang and B. Tan, Acc. Chem. Res., 2022, 55, 2920–2937 CrossRef CAS PubMed.
  24. D. Liang, W. Xiao, S. Lakhdar and J. Chen, Green Synth. Catal., 2022, 3, 212–218 CAS.
  25. J. K. Cheng, S.-H. Xiang, S. Li, L. Ye and B. Tan, Chem. Rev., 2021, 121, 4805–4902 CrossRef CAS PubMed.
  26. J. Wencel-Delord, A. Panossian, F. R. Leroux and F. Colobert, Chem. Soc. Rev., 2015, 44, 3418–3430 RSC.
  27. A. Link and C. Sparr, Chem. Soc. Rev., 2018, 47, 3804–3815 RSC.
  28. Z.-X. Zhang, T.-Y. Zhai and L.-W. Ye, Chem Catal., 2021, 1, 1378–1412 CAS.
  29. Y.-J. Wu, G. Liao and B.-F. Shi, Green Synth. Catal., 2022, 3, 117–136 Search PubMed.
  30. G. Centonze, C. Portolani, P. Righi and G. Bencivenni, Angew. Chem., Int. Ed., 2023, 62, e202303966 CrossRef PubMed.
  31. D. Wang, J. Zong, B. Wang, L. Sun, X. Xiao, H. Piao, M. Ke and F. Chen, Green Synth. Catal., 2025, 6, 211–215 CAS.
  32. W. Su, J. Zhu, Y. Chen, X. Zhang, W. Qiu, K. Yang, P. Yu and Q. Song, Nat. Chem., 2024, 16, 1312–1319 CrossRef CAS PubMed.
  33. L. Li, S. Wang, A. Jakhar and Z. Shao, Green Synth. Catal., 2023, 4, 124–134 CAS.
  34. R. K. Neff and D. E. Frantz, ACS Catal., 2014, 4, 519–528 CrossRef CAS.
  35. K. Yang, Y. Mao, Z. Zhang, J. Xu, H. Wang, Y. He, P. Yu and Q. Song, Nat. Commun., 2023, 14, 4438 CrossRef CAS.
  36. Z.-L. Wang and Y.-H. Xu, Synthesis, 2023, 56, 1259–1272 Search PubMed.
  37. F. Hu and Y. Xia, Eur. J. Org Chem., 2023, 26, e202300151 CrossRef CAS.
  38. H. J. Bestmann and J. Lienert, Angew. Chem., Int. Ed., 1969, 8, 763–764 CrossRef CAS.
  39. S. Hanessian, D. Delorme, S. Beaudoin and Y. Leblanc, J. Am. Chem. Soc., 1984, 106, 5754–5756 CrossRef CAS.
  40. S. E. Denmark and C. T. Chen, J. Am. Chem. Soc., 1992, 114, 10674–10676 CrossRef CAS.
  41. A. Abiko and S. Masamune, Tetrahedron Lett., 1996, 37, 1077–1080 CrossRef CAS.
  42. W.-M. Dai, J. Wu and X. Huang, Tetrahedron: Asymmetry, 1997, 8, 1979–1982 CrossRef CAS.
  43. M. Mizuno, K. Fujii and K. Tomioka, Angew. Chem., Int. Ed., 1998, 37, 515–517 CrossRef CAS PubMed.
  44. M. Iguchi and K. Tomioka, Org. Lett., 2002, 4, 4329–4331 CrossRef CAS.
  45. J. C. Fiaud and J. Y. Legros, Tetrahedron Lett., 1988, 29, 2959–2962 CrossRef CAS.
  46. T. Kratz, P. Steinbach, S. Breitenlechner, G. Storch, C. Bannwarth and T. Bach, J. Am. Chem. Soc., 2022, 144, 10133–10138 CrossRef CAS PubMed.
  47. G. Zeng, W. Shi, Z. Wang, X. Zhao, Y. Yin and Z. Jiang, J. Am. Chem. Soc., 2025, 147, 26079–26088 CrossRef CAS.
  48. J. M. Wahl, M. L. Conner and M. K. Brown, J. Am. Chem. Soc., 2018, 140, 15943–15949 CrossRef CAS.
  49. W. Xiao, L. Ning, S. Xin, S. Dong, X. Liu and X. Feng, Angew. Chem., Int. Ed., 2022, 61, e202211596 CrossRef CAS.
  50. Y. Chen, J. Chen and S. Zhu, ACS Cent. Sci., 2025, 11, 899–909 CrossRef CAS.
  51. S. Wang, J. Liu, W. Ma and Q. Song, Sci. China Chem., 2025, 68, 1929–1936 CrossRef CAS.
  52. B. Wang, J. Zhao, J. Ying, B. Cheng and Z. Lu, Angew. Chem., Int. Ed., 2025, 64, e202421500 CrossRef CAS.
  53. B.-R. Shao, W.-F. Jiang, C. Wang and L. Shi, Angew. Chem., Int. Ed., 2025, 64, e202421287 CrossRef CAS.
  54. B. Gong, Q. Lu, R. Sun, Z. Li, Y. Chen, A. Lin, H. Yao and S. Gao, ACS Catal., 2025, 15, 2351–2358 CrossRef CAS.
  55. J. Hurtado, N. Iragorri, E. Reyes, J. L. Vicario and E. Fernández, Angew. Chem., Int. Ed., 2024, 63, e202411232 CAS.
  56. C. Sun, T. Qi, F.-U. Rahman, T. Hayashi and J. Ming, Nat. Commun., 2024, 15, 9307 CrossRef CAS.
  57. S.-J. He, B. Shen, L.-Z. Zuo, S.-H. Xiang, H.-H. Liu, P. Yu and B. Tan, J. Am. Chem. Soc., 2024, 146, 19137–19145 CrossRef CAS PubMed.
  58. B.-R. Shao, W.-F. Jiang, C. Zheng and L. Shi, Chem Catal., 2023, 3, 100697 CAS.
  59. C. Ma, Y. Sun, S. Liu, Z.-M. Li, J. Yang, H. Guo and J. Zhang, Chem Catal., 2022, 2, 3196–3206 CAS.
  60. S. Li, J.-L. Xu and Y.-H. Xu, Org. Lett., 2022, 24, 6054–6059 CrossRef CAS PubMed.
  61. J. Janabel, D. Kumar, V. V. Kanale, M. Liu and C. Uyeda, J. Am. Chem. Soc., 2025, 147, 23270–23276 CrossRef CAS.
  62. M. Arnold, J. Hammes, M. Ong, C. Mück-Lichtenfeld and J. M. Wahl, Angew. Chem., Int. Ed., 2025, 64, e202503056 CrossRef CAS.
  63. X.-Y. Wang, X.-Z. Xie, Z.-W. Wu, Y. Bai, Y. Chen and J.-S. Yu, Synthesis, 2024, 56, 3879–3888 CrossRef CAS.
  64. J. Z. Essman and E. N. Jacobsen, J. Am. Chem. Soc., 2024, 146, 7165–7172 CrossRef CAS PubMed.
  65. M. Ying, K. Wang, W. Yan, M. Pu and L. Lin, Chem.–Eur J., 2024, 30, e202401243 CrossRef CAS.
  66. S.-J. He, S. Zhu, S.-Q. Qiu, W.-Y. Ding, J. K. Cheng, S.-H. Xiang and B. Tan, Angew. Chem., Int. Ed., 2023, 62, e202213914 CrossRef CAS PubMed.
  67. S. Zhu, J.-H. Mao, J. K. Cheng, S.-H. Xiang and B. Tan, Chem, 2022, 8, 2529–2541 CAS.
  68. S. Crotti, N. Di Iorio, C. Artusi, A. Mazzanti, P. Righi and G. Bencivenni, Org. Lett., 2019, 21, 3013–3017 CrossRef CAS.
  69. S. K. Nimmagadda, S. C. Mallojjala, L. Woztas, S. E. Wheeler and J. C. Antilla, Angew. Chem., Int. Ed., 2017, 56, 2454–2458 CrossRef CAS.
  70. L. Gramigna, S. Duce, G. Filippini, M. Fochi, M. C. Franchini and L. Bernardi, Synlett, 2011, 18, 2745–2749 Search PubMed.
  71. S. Arai, S. Hamaguchi and T. Shioiri, Tetrahedron Lett., 1998, 39, 2997–3000 CrossRef CAS.
  72. Y. Yan, Q. Wei, Z. Su, N.-N. Hang, T. Hayashi and J. Ming, Nat. Commun., 2024, 15, 9915 CrossRef CAS PubMed.
  73. M. A. Saucier, N. A. Kruse, B. E. Seidel, N. I. Hammer, G. S. Tschumper and J. H. Delcamp, J. Org. Chem., 2024, 89, 9092–9097 CrossRef CAS.
  74. J. Liu, M. Liu, H. Zhang and W. Guo, Angew. Chem., Int. Ed., 2021, 60, 12992–12998 CrossRef CAS PubMed.
  75. M. Grzybowski, M. Taki, K. Kajiwara and S. Yamaguchi, Chem.–Eur J., 2020, 26, 7912–7917 CrossRef CAS PubMed.
  76. X. He, J.-B. Lin, W. H. Kan and T. Baumgartner, Angew. Chem., Int. Ed., 2013, 52, 8990–8994 CrossRef PubMed.
  77. Z.-D. Li, F. Ren, Y. Wu, J.-J. Li, J. Luo and P. Wang, Org. Lett., 2024, 26, 7436–7441 CrossRef CAS.
  78. X. Zhang, J.-Q. Zhang, Z.-H. Sun, H.-M. Shan, J.-C. Su, X.-P. Ma, G.-F. Su, L.-P. Xu and D.-L. Mo, Angew. Chem., Int. Ed., 2025, 64, e202420390 CrossRef CAS.
  79. (a) CCDC 2478635: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2p66z3.; (b) CCDC 2478637: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2p6716.

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.